WADA raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-05. Anything still debated is marked as such rather than presented as settled.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
16 February – The RMT announce four new days of train strikes for 16, 18 and 30 March, and 1 April. 17 February David Ballantyne Smith, a former security guard at the British embassy in Berlin who attempted to sell confidential information to the Russians, is sentenced to 13 years imprisonment following a trial at the Old Bailey. Storm Otto strikes Scotland and parts of northern England, leaving around 30,000 homes without power and forcing a number of schools to close. COVID-19 in the UK: Office for National Statistics data for the week up to 7 February indicates that COVID-19 cases continued to increase in England, Wales and Scotland, but decreased in Northern Ireland. In England, In England it is estimated that 1,054,200 people had COVID-19, equating to 1.88% of the population, or around 1 in 55 people. 18 February – Coronation of Charles III and Camilla: Twelve new pieces of music are commissioned by the King for his coronation, including a composition by Andrew Lloyd Webber. Part of the service will also be in Welsh, it is confirmed. 19 February – Police searching for Nicola Bulley, missing since 27 January, announce they have found a body in the River Wyre. 20 February Lancashire Police confirm the body found in the River Wyre the previous day is that of Nicola Bulley. Prime Minister Rishi Sunak criticises the rewriting of Roald Dahl's books after they were updated to remove references that could be considered offensive, such as characters being fat.
The Fo transmembrane domain is involved in the movement of ions across the membrane. The bacterial FoF1-ATPase consists of the soluble F1 domain and the transmembrane Fo domain, which is composed of several subunits with varying stoichiometry. There are two subunits, γ, and ε, that form the central stalk and they are linked to Fo. Fo contains a c-subunit oligomer in the shape of a ring (c-ring). The α subunit is close to the subunit b2 and makes up the stalk that connects the transmembrane subunits to the α3β3 and δ subunits. F-ATP synthases are identical in appearance and function except for the mitochondrial FoF1-ATP synthase, which contains 7-9 additional subunits. The electrochemical potential is what causes the c-ring to rotate in a clockwise direction for ATP synthesis. This causes the central stalk and the catalytic domain to change shape. Rotating the c-ring causes three ATP molecules to be made, which then causes H+ to move from the P-side (positive-side) of the membrane to the N-side (negative-side) of the membrane. The counterclockwise rotation of the c-ring is driven by ATP hydrolysis and ions move from the N-side to the P-side, which helps to build up electrochemical potential.
Former interim leader of the party and MLA for Surrey-White Rock Trevor Halford, former leader and MLA for Nechako Lakes John Rustad, and MLA for Skeena Claire Rattée were all removed. Rattée issued a statement claiming Findlay was “attempting to oust members of her own caucus, demonstrating poor judgement that doesn’t befit someone who is attempting to become premier.” Since July 2026, multiple staffers have also resigned from the party, including former executive director Angelo Isidorou, former party president Aisha Estey and former vice-president Sharon White. These positions have been replaced by many controversial figures, including Apollo Chung, a former member of the separatist Republican Party of Alberta, and Chris Delaney, notable for his ties to former British Columbia Premier Bill Vander Zalm. In September 2026, allegations emerged that Findlay had hired a private investigator to watch Conservative critics, including sitting Conservative MLAs and a journalist. Findlay claims she was "unaware." MLA for Skeena Claire Rattée, who identified herself as one of the targets, said at least 10 members of caucus have signed a letter asking Findlay to resign. Rattée was later removed from caucus by Findlay. Former Conservative MLA Brennan Day, and former party executive director Angelou Isidorou also identified themselves as alleged targets. On September 20, 2026, Findlay announced her resignation as leader of the Conservative Party of BC.
== Classification == Kwashiorkor is a type of severe acute malnutrition (SAM). SAM is a category, composed of two conditions: marasmus and kwashiorkor. Both kwashiorkor and marasmus fall under the umbrella of protein–energy malnutrition (PEM). These diseases are oftentimes discussed together, but are distinctly separate conditions of malnutrition. Kwashiorkor is marked by an array of metabolic disturbances of uncertain cause. In contrast, marasmus is more clearly an energy deficiency syndrome, marked by weight loss. On physical exam, kwashiorkor is also distinguished from marasmus by the presence of edema. When children present with both kwashiorkor and marasmus, the condition is referred to as "marasmic-kwashiorkor". In general, kwashiorkor is marked by more profound serum depletions of antioxidant molecules and minerals, relative to marasmus.
Acecarbromal (INN) (brand names Sedamyl, Abasin, Carbased, Paxarel, Sedacetyl, numerous others), also known as acetylcarbromal and acetyladalin, is a hypnotic and sedative drug of the ureide (acylurea) group discovered by Bayer in 1917 that was formerly marketed in the United States and Europe. It is also used in combination with extract of quebracho and vitamin E as a treatment for erectile dysfunction under the brand name Afrodor in Europe. Acecarbromal is structurally related to the barbiturates, which are basically cyclized ureas. Prolonged use is not recommended as it can cause bromine poisoning.
Sources: en.wikipedia.org
Calibration of the system was carried out initially using a flight of mostly civilian-flown, impressed Avro Rota autogyros flying over a known landmark, the radar then being calibrated so that the position of a target relative to the ground could be read off the CRT. The Rota was used because of its ability to maintain a relatively stationary position over the ground, the pilots learning to fly in small circles while remaining at a constant ground position, despite a headwind. The rapid expansion of the CH network necessitated more technical and operational personnel than the UK could provide, and in 1940, a formal request was made by the British High Commission, Ottawa to the Canadian Government, appealing for men skilled in radio technology for the service of the defence of Great Britain. By the end of 1941, 1,292 trained personnel had enlisted and most were rushed to England to serve as radar mechanics.
Germany's system of hospitals, called Krankenhäuser, dates from medieval times, and the country has the world's oldest universal health care system, dating from Bismarck's social legislation of the 1880s. Since the 1880s, reforms and provisions have ensured a balanced health care system. The population is covered by a health insurance plan provided by statute, with criteria allowing some groups to opt for a private health insurance contract. According to the World Health Organization (WHO), Germany's health care system was 77% government-funded and 23% privately funded in 2013. In 2024, Germany spent 12.27% of its GDP on health care. Germany ranked 21st in the world in 2019 in life expectancy with 78.7 years for men and 84.8 years for women according to the WHO, and it had a very low infant mortality rate of 4 deaths per 1,000 live births. In 2019, the principal cause of death was cardiovascular disease, at 37%. Obesity in Germany has been increasingly cited as a major health issue: a 2014 study showed that 52 percent of the adult German population was overweight or obese. Germany has an extensive psychiatric care system, with rising demand for mental health services; roughly 27.8% of adults experience a mental disorder annually. While the system offers comprehensive, insurance-covered care, it faces a shortage of psychotherapists and a pandemic-driven surge in anxiety and depression. In 2023, 37.7% of adults rated their mental health as excellent or very good. Germany had the third-highest rate of chronic depression among EU countries in 2019.
The surgeon cuts the cartilage portion of the hump with a scalpel, and chisels the bone portion with an osteotome (bone chisel). After chiselling away the main mass of the nasal hump with an osteotome, the surgeon then sculpts, refines, and smoothens the cut nasal bones with rasps (files).
L94A1 is the British Ministry of Defence designation for the long-barrelled version of the Hughes EX-34 7.62 mm chain gun, which is fitted to several British Army armoured fighting vehicles, including the Challenger 2 and the Warrior. A second version with a shorter barrel, designated L95A1, was also procured in small numbers. The weapon was produced by Heckler & Koch in the UK.
==== Entrepreneurial ==== The entrepreneurial model looks at either the individual criminal or a smaller group of organized criminals, that capitalize off the more fluid 'group-association' of contemporary organized crime. This model conforms to social learning theory or differential association in that there are clear associations and interaction between criminals where knowledge may be shared, or values enforced, however, it is argued that rational choice is not represented in this. The choice to commit a certain act, or associate with other organized crime groups, may be seen as much more of an entrepreneurial decision – contributing to the continuation of a criminal enterprise, by maximizing those aspects that protect or support their own individual gain. In this context, the role of risk is also easily understandable, however it is debatable whether the underlying motivation should be seen as true entrepreneurship, or entrepreneurship as a product of some social disadvantage. The criminal organization, much in the same way as one would assess pleasure and pain, weighs such factors as legal, social and economic risk to determine potential profit and loss from certain criminal activities. This decision-making process rises from the entrepreneurial efforts of the group's members, their motivations and the environments in which they work.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.